EU Oral Semaglutide Approval Boosts Weight Management Options

The European Commission has authorized once-daily oral semaglutide 25 mg under the EU Oral Semaglutide Approval, marking the first glucagon-like peptide-1 receptor agonist available in tablet form for weight management in adults with obesity or overweight plus at least one weight-related comorbidity when combined with diet and exercise. A single-dose pen containing the 7.2 mg injectable formulation was also cleared for the same population.

The decision followed clear body-weight reductions shown with caloric restriction and increased physical activity.

Trial Programme Backbone

Data came from the OASIS clinical development programme, a series of phase 3 studies involving about 1,300 adults who met the required body-mass-index criteria. In the 64-week OASIS 4 trial, oral semaglutide 25 mg was compared with placebo against a background of lifestyle intervention for every participant. Safety findings were interpreted against the established profile of injectable semaglutide.

Weight-Reduction Results

Patients given oral semaglutide 25 mg recorded a mean 17 percent weight loss versus 3 percent with placebo. Roughly one-third reached at least 20 percent loss under the trial product estimand. Discontinuation rates due to adverse events stayed comparable to placebo at 6.9 percent versus 5.9 percent.

Future Access and Value

Availability of both the oral tablet and the simplified higher-dose pen could shape prescriber and patient choices once the product reaches more European markets in the second half of 2026. Health technology assessment bodies will weigh the reported weight-loss figures and tolerability data when judging added benefit over current injectable options. This fifth regulatory clearance worldwide points to broader geographic expansion that may influence formulary decisions and reimbursement talks across member states.